Published in Leukemia on January 09, 2014
Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3. Oncotarget (2015) 0.91
Myxoma Virus Induces Ligand Independent Extrinsic Apoptosis in Human Myeloma Cells. Clin Lymphoma Myeloma Leuk (2015) 0.83
Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2--implications for a combinatorial treatment. Oncotarget (2015) 0.81
Novel strategies to target the ubiquitin proteasome system in multiple myeloma. Oncotarget (2016) 0.80
Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma. Oncotarget (2016) 0.78
IAP antagonists induce anti-tumor immunity in multiple myeloma. Nat Med (2016) 0.78
Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001. Leuk Res (2014) 0.76
The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock. Oncogenesis (2016) 0.76
Post-translational modification profiling - A novel tool for mapping the protein modification landscape in cancer. Exp Biol Med (Maywood) (2016) 0.75
A dominant-negative F-box deleted mutant of E3 ubiquitin ligase, β-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice. Oncotarget (2015) 0.75
Combined expression of miR-34a and Smac mediated by oncolytic vaccinia virus synergistically promote anti-tumor effects in Multiple Myeloma. Sci Rep (2016) 0.75
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22
IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell (2007) 8.48
Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity (1999) 7.78
IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell (2007) 7.74
Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov (2008) 7.64
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell (2007) 7.24
IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol (2002) 7.23
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell (2007) 7.10
cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell (2008) 5.89
Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med (1987) 4.21
Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep (2006) 4.15
IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. J Clin Invest (2005) 4.07
Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov (2012) 3.88
Structural basis of IAP recognition by Smac/DIABLO. Nature (2001) 3.66
c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem (2008) 3.54
Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature (2000) 3.54
Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer (2009) 3.45
Bcl-2 family proteins and cancer. Oncogene (2008) 3.42
Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature (2001) 3.22
Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood (1996) 2.98
Life and death by death receptors. FASEB J (2009) 2.39
Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment. J Cell Biol (2009) 2.02
Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood (2010) 1.96
Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood (2008) 1.85
TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation. Cell Death Differ (2012) 1.72
Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem (2007) 1.65
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood (2006) 1.56
The emerging role of CXCL10 in cancer (Review). Oncol Lett (2011) 1.54
Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression. Proc Natl Acad Sci U S A (2010) 1.42
Transfer of extracellular vesicles during immune cell-cell interactions. Immunol Rev (2013) 1.25
NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell (2013) 1.25
Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia (2002) 1.24
Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol (2012) 1.21
The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia (2010) 1.20
IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol (2006) 1.18
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene (2009) 1.18
Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2. Cell Death Differ (2011) 1.18
Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. Mol Cancer Ther (2011) 1.09
Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation. Cancer Discov (2012) 1.04
MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma. Leukemia (2011) 0.98
Impact of XIAP protein levels on the survival of myeloma cells. Haematologica (2008) 0.96
TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells. Am J Hematol (2010) 0.95
Ripoptosome: a novel IAP-regulated cell death-signalling platform. J Mol Cell Biol (2011) 0.94
Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway. PLoS One (2012) 0.93
Induction of the DNA damage response by IAP inhibition triggers natural immunity via upregulation of NKG2D ligands in Hodgkin lymphoma in vitro. Biol Chem (2013) 0.82
Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy. Cancer Immunol Immunother (2012) 0.81
Cell Trafficking in Multiple Myeloma. Open J Hematol (2012) 0.79